ArticleTargeted oncology2022

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Takashi Niizeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.